{"id":22607,"date":"2022-12-19T10:00:56","date_gmt":"2022-12-19T09:00:56","guid":{"rendered":"https:\/\/idibell.cat\/?p=22607"},"modified":"2022-12-16T15:59:55","modified_gmt":"2022-12-16T14:59:55","slug":"la-fundacio-hna-collabora-en-el-desenvolupament-dun-nou-farmac-contra-les-malalties-inflamatories-intestinals","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2022\/12\/la-fundacio-hna-collabora-en-el-desenvolupament-dun-nou-farmac-contra-les-malalties-inflamatories-intestinals\/","title":{"rendered":"La fundaci\u00f3 hna col\u00b7labora en el desenvolupament d’un nou f\u00e0rmac contra les malalties inflamat\u00f2ries intestinals"},"content":{"rendered":"
Fundaci\u00f3 hna col\u00b7labora amb la investigaci\u00f3 de les malalties inflamat\u00f2ries intestinals de l’IDIBELL, en concret al grup de \u201cProcessos Immunoinflamatoris i Ter\u00e0pia G\u00e8nica<\/em>\u201d, liderat pel Dr. Josep Maria Aran. Amb aquesta donaci\u00f3 es podr\u00e0 impulsar el desenvolupament d’un nou f\u00e0rmac per al tractament de les malalties inflamat\u00f2ries intestinals (MII), segons ha destacat l’investigador, que ha transm\u00e8s el seu gran agra\u00efment a la Fundaci\u00f3.<\/p>\n A Espanya la incid\u00e8ncia de les MII \u00e9s de 16 casos cada 100.000 persones\/any, fet que suposa aproximadament 10.000 nous casos cada any. En aquestes malalties autoinflamat\u00f2ries una regulaci\u00f3 an\u00f2mala del sistema immune causa una inflamaci\u00f3 persistent al tracte gastrointestinal. Les MII suposen una c\u00e0rrega important per al sistema de salut. Per altra banda, els tractaments actuals s\u00f3n poc efica\u00e7os i tenen efectes secundaris molt importants.<\/p>\n El grup del Dr. Aran ha descobert una prote\u00efna que \u00e9s capa\u00e7 de fer que les c\u00e8l\u00b7lules del sistema immunitari passin d’estar d’un estat proinflamatori a un estat antiinflamatori, cosa que podria frenar la progressi\u00f3 d’aquestes malalties. El compost en q\u00fcesti\u00f3 correspon a una reestructuraci\u00f3 duna prote\u00efna reguladora del sistema immunitari innat, la primera l\u00ednia de defensa del nostre cos.<\/p>\n Amb aquest projecte finan\u00e7at per la Fundaci\u00f3 hna, els investigadors pretenen desenvolupar i caracteritzar a trav\u00e9s de tecnologies d’avantguarda aquest nou immunomodulador biol\u00f2gic.<\/p>\n <\/p>\n <\/p>\n L\u2019Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l’Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l’Institut Catal\u00e0 de la Salut, l’Institut Catal\u00e0 d’Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n L\u2019IDIBELL \u00e9s membre del Campus d’Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L’any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":" Aquest suport ajudar\u00e0 a desenvolupar i caracteritzar un nou compost immunomodulador descobert pel grup de l’IDIBELL liderat pel Dr. Josep Maria Aran.<\/p>\n","protected":false},"author":8,"featured_media":22608,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[334,464,378],"tags":[],"class_list":["post-22607","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicina-translacional","category-p-de-gens-malaltia-i-terapia","category-processos-immune-inflamatoris-i-terapia-genica"],"publishpress_future_action":{"enabled":false,"date":"2024-12-29 07:28:54","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22607","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=22607"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22607\/revisions"}],"predecessor-version":[{"id":22609,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22607\/revisions\/22609"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/22608"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=22607"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=22607"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=22607"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}